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Abstract Reactivation of telomerase has been implicated in human 
tumourigenesis, but the underlying mechanisms remain poorly understood. 
Here, we report the presence of recurrent somatic mutations in TERT promoter 
in cancers of the central nervous system, (43%), bladder (59%), thyroid 
(follicular cell-derived) (10%) and skin (melanoma, 29%). We also show that, in 
central nervous system and thyroid cancers, the presence of TERT promoter 
mutations is associated with increased telomerase and TERT mRNA 
expression, respectively, and older age of the patients. Our results show that 
TERT promoter mutations are frequently found in specific types of human 
cancers, where they lead to enhanced expression of telomerase/TERT. 
Introduction 
Reactivation or re-expression of telomerase is referred to be a widespread 
feature in human cancers, although the genetic basis remains poorly 
understood in many cancer types. Somatic mutations in the coding region of 
TERT (human telomerase reverse transcriptase) are infrequent in human 
tumours, but germline and somatic mutations in TERT promoter were recently 
found in a high percentage of human melanomas and human cancer cell 
lines1,2. Such mutations occurred in two hotspot positions, located -124bp and -
146bp upstream from the ATG start site (-124G>A and -146G>A, C>T on 
opposite strand) and conferred enhanced TERT promoter activity1,2, by 
putatively generating a consensus binding site (GGAA) for ETS transcription 
factors  within the TERT promoter region1,2. 
Our aim was to investigate whether the aforementioned TERT promoter 
mutations were present in cancer types other than melanoma, having for that 
matterscreened 741 primary tumours from the thyroid, kidney, bladder, 
gastrointestinal stroma (GISTs), adrenal medulla (phaeochromocytomas) and 
central nervous system (CNS). Besides skin melanoma, we have also included 
ocular melanoma (not studied in the previous reports), benign lesions of the 
thyroid and skin and 58 human cancer-derived cell lines.  Our results highlight 
TERT promoter mutations as frequent events in specific types of human 
cancers. 
 
Results 
Overall, TERT promoter mutations were found in 142 (19%) human tumour 
samples (Table 1, Fig. 1A) and in 14 (24%) human cell lines (Supplementary 
Fig.1, Supplementary Table 1 and 2). The -124bp mutation was the most 
frequent, being present in 99 cases, whereas the -146bp was present in 43 
cases. The -124G>A and -146G>A mutations were found in a mutually 
exclusive fashion. Two tandem GG>AA mutations at positions -124/-125bp and 
-138/-139bp were observed in one cell line each (Fig. 1, bottom, Supplementary 
Table 1). TERT promoter mutations were not detected in normal thyroid tissue 
or in benign lesions (nevi, thyroiditis, goitres and adenomas). No mutations 
were detected in 26 kidney cancers, 17 phaeochromocytomas, and 36 GISTs. 
We have analysed both skin and ocular melanomas, a type of melanoma that 
was not previously studied1,2. TERT mutations were present in 16 out of 56 
(29%) skin melanomas, but absent in the 25 ocular melanomas (Table 1). All 
the 4 skin melanoma-derived cell lines but none of the 6 ocular melanoma-
derived cell lines harboured TERT mutations (Supplementary Table 1 and 
Supplementary Fig. 1). Ten out 16 (63%) skin melanomas with TERT mutation 
also harboured the BRAFV600E mutation whereas the BRAF mutation was 
present in 9 out 38 (24%) of the melanomas without TERT mutation (p=0.01) 
(Supplementary Fig. 2).  
In CNS tumours TERT promoter mutations were found in 43% (51/118) of all 
cases with an equal prevalence of both mutations (Table 1, and Supplementary 
Table 4). The frequency of TERT mutations was different according to the 
tumour histology and grade (Fig 1C): while pilocytic astrocytomas (WHO grade 
1) and diffuse astrocytoma (WHO grade 2) showed a lower frequency of 
mutations (8% and 15% respectively), the most aggressive form, glioblastoma 
multiforme (GBM; WHO grade 4) present the highest frequency of TERT 
mutations (62%). Oligodendrogliomas (WHO grade 2) and anaplastic 
oligodendrogliomas (WHO grade 3) also harboured a high frequency of TERT 
mutations (45% and 54% respectively).  
The presence of TERT mutations was significantly associated with a higher 
mean age at diagnosis (Supplementary Table 5) in CNS patients as a whole 
(p<0.0001) and also in GBM patients only (p=0.0247); in oligodendroglioma 
patients, we found the same trend, although not statistically significant 
(p=0.0709). Additionally, we observed that, in a subset of 14 GBM (8 TERT wt 
tumours and 6 TERT mutated tumours), the tumours with TERT mutations 
showed increased expression of telomerase (Fig. 2). 
We analysed a large series of follicular cell-derived thyroid samples including 
normal thyroid (n=27), benign (n=81) and malignant lesions (n=263) 
(Supplementary Table 6). TERT mutations were only detected in malignant 
tumours (10%) (Fig. 1B), namely in 11% of papillary thyroid carcinomas (PTC), 
14% of follicular thyroid carcinomas (FTC), 21% of poorly differentiated thyroid 
carcinoma (PDTC) and 13% of the anaplastic carcinomas. Within the group of 
PTC, TERT mutations were detected associated to the in the so-called 
conventional PTC (cPTC) (11%).The majority of TERT-mutated thyroid cancers 
harboured the -124G>A mutation (22 out of 27 cases) (Figure 1B, 
Supplementary Table 7). In thyroid cancer patients, TERT mutations were 
significantly associated with guarded prognosis features such as larger tumours 
(p=0.008), older patients (p<0.0001) and male gender (p=0.03) (Supplementary 
Table 5). After histotype stratification, such correlations were only kept in the 
group of cPTC where we also found significant associations with lymph node 
metastasis (p=0.03) and BRAFV600E mutation (p=0.001) (Supplementary 
Table 8).  Accordingly, we verified by quantitative RT-PCR that TERT mRNA is 
expressed at variable amounts in thyroid tumours, and the ones with coexistent 
TERT and BRAF mutations showed the highest levels of TERT mRNA 
expression (p<0.005; Figure 3).   
In bladder cancer, TERT mutations were frequently detected (48/82; 59%) both 
in low grade tumours (14/21; 67%) and in high grade tumours (34/61; 56%) 
(Table 1 and Fig. 1D; Supplementary Table 9). The -124G>A mutation was 
present in 30 cases while the -146 G>A was found in 18 cases. No association 
was found between the presence of the mutation and the age of the patients. 
No mutations were detected in 26 kidney cancers, 17 non-metastatic 
phaeochromocytoma, and 36 non-metastatic GISTs (Supplementary Table 10, 
11 and 12, respectively).  
Discussion 
From recent findings TERT promoter mutations arise as a novel mechanism of 
telomerase reactivation/expression in human cancers1,2. In this work we report 
for the first time the presence of these mutations in different histotypes of 
thyroid cancer and our results validate the findings reported by others in 
melanoma, bladder and gliomas1-3. Furthermore we present the first evidence 
that TERT promoter mutations are associated with increased telomerase 
expression in gliomas and with increased TERT mRNA expression in thyroid 
cancers. In the latter, TERT mRNA was particularly high in cases harbouring 
both TERT and BRAF mutations.  
The location of these mutations in the TERT promoter, rather than the coding 
region of the gene, creating additional binding sites for transcription factors, 
represents also a novel mechanism of genetic activation in cancer.  
The frequency of TERT mutations we detected in skin melanomas is similar to 
the one reported by Horn et al. in primary melanomas (33%)1, but lower than 
the frequency found by the same authors in metastatic melanomas (85%) and 
by Huang et al.2 in a series of 70 melanomas and short term cultures1,2. In our 
series, we have analysed few metastatic melanomas that did not show a 
significantly higher percentage of TERT mutations. Since our series is too small 
to allow a conclusion, it remains to be verified if there is an increased frequency 
of TERT mutations in metastatic melanomas, as suggested by previous 
reports1,2.  
We have confirmed, in skin melanomas, the significant association between 
TERT mutations and BRAF mutations, as previously advanced by Horn et al.1 
and that we now also demonstrate in thyroid cancers (see below). Interestingly, 
in benign nevi, that frequently harbour BRAF mutations, we did not detect TERT 
mutations. This finding, together with the high frequency of TERT mutations in 
metastatic melanomas1 suggests that, while BRAF mutations are thought to be 
an early event in melanoma genesis, TERT mutations may occur at a later 
stage.  
No TERT promoter mutations were found in ocular melanomas, which, at 
variance with skin melanomas, harbour GNAQ mutations instead of BRAF 
mutations4,5. Our results thus support the assumption that ocular melanomas 
result from different etiopathogenic mechanism than skin melanomas5,6. 
Our data on CNS tumours indicate that TERT promoter mutations are frequent 
events in gliomas, particularly in GBM where the highest mutation frequency 
was found. While others1,2 had shown that such mutations conferred enhanced 
TERT promoter activity in vitro, we present evidence that GBM with TERT 
promoter mutations have increased telomerase expression. Our results also fit 
with those of Lotsch et al.7 who reported that 60% of GBM were positive for 
TERT mRNA and telomerase activity7. It will be interesting to assess whether 
the GBM positive for telomerase activity described by Lotsch et al.7, also 
harbour TERT promoter mutations. Our findings also indicate that TERT 
mutations are associated with older patients, in accordance with a recent 
report3.  The high frequency of TERT mutations in CNS tumours, particularly in 
intermediate and high grade tumours, opens a window for new approaches in 
the therapy of CNS tumours.  
In thyroid cancer TERT mutations were only found in follicular cell-derived 
cancers (PTC, FTC, PDTC and ATC). No mutations were detected in medullary 
thyroid carcinomas, as advanced by Killela et al.3, or in normal thyroid, and 
benign lesions, such as goitre, adenomas or thyroiditis; this finding fits with 
previous studies that reported telomerase expression in malignant lesions and 
not in normal tissue or hyperplastic lesions8,9. TERT mutations were associated 
with clinico-pathological features (older age, increased tumour size and male 
gender) but, after histotype stratification, these associations were only 
maintained in cPTC. Studies in larger series will be necessary to clarify these 
associations. In cPTC TERT mutations were associated with BRAF mutation, 
highlighting the coexistence of activation of BRAF and TERT, previously 
reported in melanoma1 (Supplementary Fig. 2). Our results reinforce the 
hypothesis of a link between BRAF activation and telomerase expression, which 
can be mediated by transcription factors binding to the newly created 
consensus binding sites, as previouslyadvanced by Horn et al1. Both in thyroid 
carcinoma and in melanoma it seems that a “background” status of activated 
BRAF enhances the effects of TERT promoter mutation. Our results in TERT 
mRNA expression strengthen this assumption, showing, for the first time, an 
increased TERT expression in tumours harbouring BRAF and TERT mutation 
(Fig 3). Further observational and mechanistic studies are needed to clarify 
these points.  
TERT alterations seem to constitute an early and frequent event in bladder 
cancer. These findings fit with the high prevalence of telomerase activity 
previously described in bladder tumours10. The recurrent hotspot mutations in 
TERT were advanced to be, in melanomas, induced by UV radiation2. Bladder 
is a target for several chemical carcinogens; it remains to be found whether 
TERT mutations can also result from the action of such agents. The 
identification of TERT mutations in urine may provide a biomarker for early 
diagnosis and monitoring of bladder cancer. 
No TERT mutations were detected in kidney cancers, nor in 17 
phaeochromocytoma, and 36 GISTs. It remains to be clarified the underlying 
reasons for the tissue specificity of TERT mutations and to be confirmed the 
association of their presence with malignancy. We can hypothesized that TERT 
mutations can be present in two settings. As advanced by Killela et al.3, TERT 
mutations can be relevant in tissues with relative low rates of self-renewal, 
which fits with our findings in follicular cell-derived thyroid cancer and gliomas 
where they are associated with the older age of the patients. On the other hand, 
these mutations can also result from environmental factors such as UV radiation 
and chemical carcinogens as suggested by their high frequency in melanoma, 
bladder and tongue1-3. In summary, our data identifies TERT mutations as 
common events in human cancers and support the assumption2 that TERT 
promoter mutations may be one of the mechanisms that underlies telomerase 
reactivation in several types of human tumours. 
 
 
 
 
 
Material and methods  
All the procedures described in this study were in accordance with national and 
institutional ethical standards. 
 
Human cancer samples 
Nevi and melanoma samples - Formalin-fixed, paraffin-embedded tissues from 9 
cases of sporadic nevi, 56 cases of sporadic skin melanomas and 25 cases of ocular 
melanoma were retrieved from the files of the Hospital S. João (HSJ)/Medical Faculty 
of Porto (FMUP), Porto, Portugal, the Department of Pathology of HSJ and the 
Department of Pathology of Hospital S. Marcos (HSM), Braga, Portugal. Clinico-
pathological and follow-up data were retrieved from the files of the Department of 
Pathology, Department of Dermatology and Oncology Registry of HSJ, Department of 
Pathology of HSM, and from RORENO (Oncology Registry of North Region). All skin 
melanoma cases were re-evaluated and staged according to the seventh edition of the 
AJCC11. The overall female to male ratio was 1.2:1. The mean age of the patients was 
58 years for females (SD±17.6), with a range from 9 to 94 years, and 62 years for 
males (SD±13.1), with a range from 33 to 79 years. 
Follow-up data were available for 53 patients, including the diagnosis of metastases, 
through the evaluation of the patients or direct interview with their relatives and by 
review of in-hospital patient files/RORENO. The mean follow-up time of patients was 
41 months (range 1 - 170). During follow-up, 5 (9%) patients developed (lymph node, 
liver or brain) metastases and 8 (15%) patients died due to malignant melanoma. The 
remaining patients were alive and without evidence of melanoma recurrence at the last 
follow-up. Additional information regarding the melanoma subtype, age, gender, 
thickness and molecular analysis of TERT, BRAF and NRAS is compiled in 
supplementary Table 3.  
Thyroid samples - Formalin-fixed, paraffin-embedded tissues from 372 tumours and 
tumour-like lesions of the thyroid and 27 normal thyroids were collected from the files of 
IPATIMUP, HSJ/FMUP and the Portuguese Institute of Oncology (IPO-C), Coimbra, 
Portugal. The histology of all tumour samples was revised and the final classification 
was made according to the WHO criteria12.  In supplementary Tables 6 and 8 we have 
summarized the information regarding histological classification of the lesions, gender, 
mean age of the patients, molecular data and the size of the tumours. 
Central Nervous System samples – Representative formalin-fixed paraffin-embedded 
samples from 118 gliomas were retrieved from pathology archives of the Department of 
Pathology of HSJ/FMUP and the Department of Pathology of Hospital S. Marcos 
(HSM), Braga, Portugal. The tumours were reviewed and classified according to the 
WHO classification of CNS tumors13,14 (, 2007). This cohort includes lesions that were 
classified as pilocytic astrocytoma (n=13), astrocytoma grade 2 (n=20), 
oligodendroglioma (n=22), anaplastic oligodendroglioma (n=24) and glioblastoma 
(n=39). Further information regarding the CNS cases is available in supplementary 
Table 4.  
Bladder - Formalin-fixed, paraffin-embedded tissues were collected from 82 patients 
with non-muscle invasive bladder cancer who underwent transurethral resection of the 
bladder malignant tumours in the Portuguese Institute of Oncology (IPO-P)-Porto. 
Haematoxylin-eosin (H&E)-stained sections were reviewed according to standard 
histopathological examination by two independent pathologists. Staging and grading 
were conducted according to the American Joint Committee on Cancer11  and to the 
2004 WHO classification systems15. Supplementary Table 9 summarizes the clinic-
pathological parameters.Kidney - Formalin-fixed, paraffin-embedded tissues from 26 
kidney cancers were collected from the HSJ/FMUP. Cases were classified as clear cell 
renal cell carcinoma (n=12), chromophobe renal cell carcinoma (n=4) and papillary 
renal cell carcinoma (n=10). Information addressing the diagnosis, age, gender, 
nuclear grade and staging is obtainable in Supplementary table 10.   
Adrenal – Formalin-fixed, paraffin-embedded tissues from 17 pheochromocytomas 
were collected from the Hospital de S. João/Medical Faculty of Porto, Porto, Portugal; 
IPATIMUP, Porto, Portugal. Supplementary Table 11 summarizes the clinic-
pathological parameters. 
GIST - Formalin-fixed, paraffin-embedded tissues from 36 GIST were collected from 
the HSJ/FMUP and IPATIMUP, Porto, Portugal. Tumours were classified according to 
WHO pathological classification16 and the parameters analysed in each case included: 
age, gender, and tumour size. These data and the molecular characterization of these 
tumors can be observed in supplementary Table 12. 
Cell lines - DNA from 58 cell lines deposited in IPATIMUP cell line bank was retrieved. 
All the cell lines were authenticated using DNA profile analysis, obtained with the 
PowerPlex 16 system (Promega, Madison, USA), according to ATCC and HSRRB 
available DNA profiles. 
 
DNA extraction 
DNA from formalin-fixed, paraffin-embedded tissues was retrieved from 10 
micrometres cuts after careful micro dissection. DNA extraction was performed using 
the Ultraprep Tissue DNA Kit (AHN Biotechnologie, Nordhausen, Germany) following 
the manufacturer’s instructions. 
 
RNA Extraction 
Total RNA was extracted from 27 frozen thyroid tumours (n=24) and normal tissue 
specimens (n=3)  using a Trizol commercial kit (Life Technologies, GIBCO BRL, 
Carlsbad, CA) according to the manufacturer’s protocol. RNA was quantified 
spectrophotometrically, and its quality was checked by analysis of 260ηm/280ηm and 
260ηm/230ηm ratios.  
 
PCR and Sanger sequencing 
Coding regions of BRAF, GNAQ HRAS, NRAS, cKIT and PDGFR were screened for 
mutations in DNA extracted from paraffin blocks using PCR and Sanger sequencing. 
The genetic characterization of part of the tumours had already been previously 
reported. Refer to these works for primers and PCR conditions information5,17,18. To 
screen for TERT promoter mutations, we analysed the hotspots previously identified by 
PCR followed by Sanger sequencing. TERT promoter mutation analysis was performed 
with the pair of primers FwTERT: CAGCGCTGCCTGAAACTC; and RwTERT: 
GTCCTGCCCCTTCACCTT. Amplification of genomic DNA (25–100 ng) was 
performed by PCR using the Qiagen Multiplex PCR kit (Qiagen, Hilden, Germany) 
following the manufacturer instructions. Sequencing reaction was performed with the 
ABI Prism BigDye Terminator Kit (Perkin-Elmer, Foster City, California) and the 
fragments were run in an ABI prism 3100 Genetic Analyser (Perkin-Elmer). The 
sequencing reaction was performed in a forward direction, and an independent PCR 
amplification/sequencing, both in a forward and reverse direction, was performed in 
positive samples or samples that were inconclusive. 
 
Quantitative RT-PCR 
q RT-PCR for human TERT was performed in 28 thyroid samples, 24 tumours and 3 
normal tissue specimens. We also included a normal reference that was produced by 
pooling RNAs from 9 samples of normal thyroid tissue19. 
For cDNA preparation, 1 μg of total RNA was reverse transcribed using the RevertAid® 
first strand cDNA synthesis kit (Fermentas, Burlington, ON, Canada). Reverse 
transcription products were amplified for the hTERT by real-time quantitative PCR (IDT, 
#HS.PT.56a.40988589) using TaqMan® PCR Master Mix (Applied Biosystems, Foster 
City, CA, USA) with TBP gene (TATA-binding protein) as endogenous control (Applied 
Biosystems, #4326322E-0705006). The ABI PRISM 7500 Fast Sequence Detection 
System (Applied Biosystems) was used to detect the amplification level and was 
programmed to an initial step of 2 minutes at 50°C, 10 minutes at 95°C, followed by 45 
cycles of 95°C for 15 seconds and 60°C for 1 minute. huTBP and hTERT amplification 
were done in triplicate using 1µl of cDNA (~50ng) for each sample. The relative 
quantification of target genes was determined using the ΔΔCT method witch was 
previously validated by Livak’s Linear Regression Method (Slope=0.0696) (Sequence 
Detector User Bulletin 2, Applied Biosystems). Primers used for qPCR are available at 
the manufacturer’s website 
Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) for telomerase was performed in representative tumor 
tissue sections of 14 glioblastomas. Briefly, deparaffinised and rehydrated sections 
were subjected to microwave treatment in 10 mM sodium citrate buffer, pH 6.0 for 
antigen retrieval. The sections were incubated overnight at 4ºC in a humidified 
chamber with the primary antibody hTERT (polyclonal, rabbit, 1:500) from Rockland 
Immunochemicals Inc., Gilbertsville, PA. The detection was performed with a labeled 
streptavidin-biotin immunoperoxidase detection system (Thermo Scientific/Lab Vision, 
Fremont, USA) and the immunohistochemical staining was developed with DAB (3,3'-
diaminobenzidine) substrate. Omission of the primary antibody incubation was used as 
negative control. Previously tested liver cancer case was used as positive control. IHC 
evaluation was performed independently by two observers (VM and JL). An IHC score 
was established, which corresponded to the product of the intensity of expression 
(absent=0, faint=1, moderate=2 strong=3) with the tumour extent of protein expression 
(0-25%=0, 26%-50%=1, 51%-75%=2, >75%=3).  
Statistical analysis 
Statistical analysis was conducted with StatView for Windows, version 5.0 (SAS 
Institute, Cary, NC). The results are expressed as a percentage or mean±SD. 
Statistical analysis was performed both on the whole series and considering the 
different groups of lesions. For the analysis of the relationship between patients’ age 
and TERT status of the tumours, we used the unpaired t-test and ANOVA. Fisher’s 
exact test was used in the statistical analysis of the other parameters. Graphs and 
figures were done in GraphPad v6.0. Results were considered statistically significant 
whenever P<0.05.  
Legend to Figures: 
Figure 1. Frequency and schematic illustration of TERT promoter mutations in 
human cancers. Graphics (A) depicts the overall frequency of TERT mutations 
in the four tumour types where TERT mutations were detected. The frequency 
and type of TERT mutations in different histological subtypes of thyroid (B), 
CNS (C) and bladder (D) tumours is also shown.  
Abbreviations: PTC-papillary thyroid carcinoma; FTC-follicular thyroid 
carcinoma; PDTC-poorly differentiated thyroid carcinoma; ATC-anaplastic 
thyroid carcinoma; PA-pilocytic astrocytoma; A-diffuse astrocytoma; O-
oligodendroglioma; AO-anaplastic oligodendroglioma; GB-glioblastoma. 
 
Figure 2 - Immunohistochemistry for TERT in two glioblastomas. Panel A 
represents a tumour without TERT expression and without TERT mutation, 
whereas panel B represents a tumour with positive staining both in nucleus and 
cytoplasm that also harboured a TERT mutation (magnification 40x). The graph 
(C) displays quantification of TERT nuclear expression level 
(immunohistochemistry) in glioblastomas with and without TERT mutation. We 
have measured the extent (less than 25%, 25-50%, 50-75% and over 75%) and 
the intensity (absent, faint, moderate or strong) of TERT nuclear staining in 14 
glioblastomas (8 TERT wt and 6 TERT mutant). The scoring was performed by 
two independent observers and is the product of extent and intensity of the 
staining (see Material and Methods). 
 
Figure 3 - Quantification of TERT mRNA expression level in thyroid tumours.  
We have performed Q-PCR in normal thyroid tissue (N), a pool of mRNA of 9 
normal thyroids (pool N) and in thyroid tumours with different genetic 
backgrounds: without known genetic alterations (WT), with BRAF mutation (B), 
with RET rearrangement (RET), with RAS mutation (R), with TERT mutation 
(T), with TERT and BRAF mutations (BT) or with RAS and TERT mutations 
(RT). In panel A each bar represents TERT mRNA expression in an individual 
tumour measured in triplicate. TERT mRNA levels were normalized against 
TBP mRNA levels. In panel B quantification of TERT mRNA mean expression 
level in thyroid tumours with and without TERT mutation. The difference is 
statistically significant (p<0.0001, unpaired T test). 
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Table 1 – Prevalence of TERT promoter recurrent mutations in human cancers 
PTC – papillary thyroid carcinoma; FTC - follicular thyroid carcinoma; PDTC – poorly differentiated thyroid 
carcinoma; ATC – anaplastic thyroid carcinoma; MTC – medullary thyroid carcinoma; CCRCC - clear cell 
renal cell carcinoma; CromRCC - chromophobe renal cell carcinoma; PRCC - papillary renal cell 
carcinoma; GIST – gastrointestinal  stromal tumor. 
 
 
 
 
 
 
Organ/tissue  Number TERT mutation N(%) 
Melanocytes    
 Nevi 9 0 
 Skin Melanoma 56 16 (29%) 
 Ocular melanoma 25 0 
CNS    
 Pilocytic Astrocytoma 13 1 (8%) 
 Diffuse Astrocytoma 20 3 (15%) 
 Oligodendroglioma 22 10 (45%) 
 Anaplastic 
Oligodendroglioma 
24 13 (54%) 
 Glioblastoma 39 24 (62%) 
Thyroid    
 Benign 81 0 
 PTC 169 13 (8%) 
 FTC 64 9 (14%) 
 PDTC 14 3 (21%) 
 ATC 16 2 (13%) 
 MTC 28 0 
Bladder    
 Low grade 21 14 (67%) 
 High grade 61 34 (56%) 
Kidney    
 CCRCC 12 0 
 CromRCC 4 0 
 PRCC 10 0 
Adrenal   
 Pheochromocytoma 17 0 
GI    
 GIST  36 0 
    
TOTAL   741 142 (19%) 
    
